APA (7th ed.) Citation

Y, P., B, J., R, A., C, C., H, Z., S, Z., . . . X, J. (2026). Tofacitinib as a Successful Treatment for Hyper-IgE Syndrome and Autoimmunity Associated with Constitutive Activation of JAK3. Journal of clinical immunology, 46(1), . https://doi.org/10.1007/s10875-026-02027-9

Chicago Style (17th ed.) Citation

Y, Pei, Jin B, Abasi R, Cheng C, Zhuang H, Zeng S, Jiang M, Pei H, and Jiang X. "Tofacitinib as a Successful Treatment for Hyper-IgE Syndrome and Autoimmunity Associated with Constitutive Activation of JAK3." Journal of Clinical Immunology 46, no. 1 (2026). https://doi.org/10.1007/s10875-026-02027-9.

MLA (9th ed.) Citation

Y, Pei, et al. "Tofacitinib as a Successful Treatment for Hyper-IgE Syndrome and Autoimmunity Associated with Constitutive Activation of JAK3." Journal of Clinical Immunology, vol. 46, no. 1, 2026, https://doi.org/10.1007/s10875-026-02027-9.